Abbisko Cayman Limited (HKG:2256)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.92
+0.40 (5.32%)
Mar 14, 2025, 4:08 PM HKT
167.57%
Market Cap 4.95B
Revenue (ttm) 536.33M
Net Income (ttm) 30.12M
Shares Out 625.26M
EPS (ttm) 0.04
PE Ratio 186.06
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,403,074
Average Volume 7,201,272
Open 7.52
Previous Close 7.52
Day's Range 7.52 - 8.10
52-Week Range 2.71 - 8.19
Beta 1.33
RSI 68.61
Earnings Date Mar 13, 2025

About Abbisko Cayman

Abbisko Cayman Limited engages in the discovering and developing small molecule oncology therapies in China. The company develops pimicotinib, which is in Phase III clinical trial for treatment of tenosynovial giant cell tumor; Irpagratinib that is in Phase II clinical trial for treatment of liver cancer; Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK043 that is in Phase I clinical trial for treatment of multiple tumors; ABSK061, ABSK121, and ABSK051, which is in Phase I clinical trial for trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 258
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2256
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.